ArticleCancers2022
Oral
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04009161 (Osteoradionecrosis Rate in Patients Undergoing Radiotherapy for Head and Neck Cancer Treatment), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Osteoradionecrosis Rate in Patients Undergoing Radiotherapy for Head and Neck Cancer Treatment: a Perspective Clinical Study.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Fluconazole for Preventing Radiation-Induced Oral Mucositis: A Randomized Controlled Trial.Head & neck · 2025Trial
- Sodium-hyaluronate mouthwash on radiotherapy-induced xerostomia: a randomised clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Antiseptic efficacy of two mouth rinses in the oral cavity to identify a suitable rinsing solution in radiation- or chemotherapy induced mucositis.BMC oral health · 2023Trial
- Article
- The effectiveness of Annona muricata for improving induced oral candidiasis in gamma-irradiated rats.BMC complementary medicine and therapies · 2026Article
- An Overview of How HNCs Radiotherapy Affects Oral Microbiota: Shifts, Complications, and Management Strategies.Journal of lasers in medical sciences · 2026Review
- Evaluation of Candida Species Colonization and Fungal Susceptibility Profile in the Oropharyngeal Mucosa of Patients Receiving Head and Neck Radiotherapy.TheScientificWorldJournal · 2026Article
- Influence of Ubiquitin Mutations over Molecular Markers Contributing to Pathogenesis of Candida albicans.Cell biochemistry and biophysics · 2025Article
- Differences in oral health status between cancer patients: a case-control observational study.BMC oral health · 2025Observational
- Article
- Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trial.Clinical and translational radiation oncology · 2025Article
- Cold Atmospheric Pressure Plasma May Prevent Oral Mucositis-Related Candidemia in Chemotherapy-Treated Rats.International journal of molecular sciences · 2024Article
- Unravelling Quality of Life for Head and Neck Cancer Patients after VMAT Radiation Therapy: Insights from Toxicity, Dosimetry and Symptoms Correlation.Clinics and practice · 2024Article
- Article
- Predictive Factors for Chemoradiation-Induced Oral Mucositis and Dysphagia in Head and Neck Cancer: A Scoping Review.Cancers · 2023Article
- Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review.Journal of personalized medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to find a correlation between
methodsThe protocol was registered on ClinicalTrials.gov (ID: NCT04009161) and approved by the ethical committee of the 'Fondazione Policlinico Universitario Gemelli IRCCS' (22858/18). An oral swab was obtained before RT to assess the presence of
resultsNo patient developed G4 OM, and only 36/152 patients (23.7%) developed G3 OM. Tumour site and lymphocytopenia were risk factors for severe OM (OR for tumour site: 1.29, 95% CI: 1-1.67,
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.